Ambitious biotech fund shuts down before first investment
Sund Capital aimed high when the investment fund, led by former Zealand Pharma CEO David Solomon, announced its ambition of raising up to DKK 2 billion for investing in promising biotech companies. Now, the fund is shutting down.
A total loss of DKK 2.9 million (nearly USD 450,000) after one and a half year now puts an end to the life-science investment fund Sund Capital that was established in the summer 2016 with an ambition of investing up to DKK 2.2 billion in Nordic biotech companies.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bionor Chairman: Solomon left of his own volition
For abonnenter
